<?xml version="1.0" encoding="UTF-8"?>
<ref id="B136-pharmaceutics-12-00688">
 <label>136.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Shah</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Doncel</surname>
    <given-names>G.F.</given-names>
   </name>
   <name>
    <surname>Seyoum</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Eaton</surname>
    <given-names>K.M.</given-names>
   </name>
   <name>
    <surname>Zalenskaya</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Hagver</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Azim</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Gross</surname>
    <given-names>R.</given-names>
   </name>
  </person-group>
  <article-title>Sophorolipids, microbial glycolipids with anti-human immunodeficiency virus and sperm-immobilizing activities</article-title>
  <source>Antimicrob. Agents Chemother.</source>
  <year>2005</year>
  <volume>49</volume>
  <fpage>4093</fpage>
  <lpage>4100</lpage>
  <pub-id pub-id-type="doi">10.1128/AAC.49.10.4093-4100.2005</pub-id>
  <?supplied-pmid 16189085?>
  <pub-id pub-id-type="pmid">16189085</pub-id>
 </element-citation>
</ref>
